Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24 months, prospective, randomized, double-blind study to assess the effect of daily oral administration of 2 g of strontium ranelate versus placebo on bone mineral density in postmenopausal osteoporotic women previously treated with oral bisphosphonates.

Trial Profile

A 24 months, prospective, randomized, double-blind study to assess the effect of daily oral administration of 2 g of strontium ranelate versus placebo on bone mineral density in postmenopausal osteoporotic women previously treated with oral bisphosphonates.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Strontium ranelate (Primary)
  • Indications Fracture; Postmenopausal osteoporosis
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 22 May 2018 Status changed from recruiting to discontinued, as per results presented at the 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
    • 22 Apr 2018 Results (n=83) assessing effect of daily oral administration of 2 g of strontium ranelate (SrRan) versus placebo over 24 months of treatment on the lumbar areal BMD in postmenopausal women with osteoporosis previously treated with bisphosphonates, were presented at the 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
    • 28 Dec 2012 Planned End Date changed from 30 Aug 2014 to 30 Aug 2015 as reported by European Clinical Trials Database.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top